Abiopharma

🔍 Wilkerson Andrew M. (Director)

Company: RXO, Inc. (RXO)

Report Date: 2026-03-22

Detailed Transactions and Holdings:

• Acquired 52,768 shares of Common Stock (Direct)
  Date: 2026-03-22 | Code: M | equity_swap_involved: 0 | shares_owned_after: 132,920.00 | transaction_form_type: 4
• Sold 22,923 shares of Common Stock at $13.23 per share (Direct)
  Date: 2026-03-22 | Code: F | equity_swap_involved: 0 | shares_owned_after: 109,997.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-22 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 7,775.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-22 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 271,767.00 | Footnotes: F2
• Sold 52,768 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-22 | Code: M | equity_swap_involved: 0 | shares_owned_after: 638,412.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: No shares were sold by the Reporting Person. These shares were withheld by the Issuer to fund tax liability attributable to the vesting and settlement of the Restricted Stock Units ("RSUs") reported on this Form 4. These RSUs vested and were settled as originally scheduled, and there were no related discretionary transactions or open market sales.
• F2: The shares are held by a limited liability company that is controlled by the Reporting Person.
• F3: Each RSU represents a contingent right to receive, upon settlement, either (i) one share of Common Stock or (ii) a cash payment equal to the fair market value of one share of Common Stock.
• F4: The RSUs vest in three equal annual installments on the first, second and third anniversaries of the grant date, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.